SAR
BADSareum Holdings Raises £125,000 Through Discounted Warrant Exercise
The biotechnology company has raised £125,000 through a discounted warrant exercise, potentially signaling financial challenges.
Sareum Holdings
16.10GBX
-5.29%
Market Cap
26.73M
Volume
11
0% of avg
P/E Ratio
-0.04
EPS (TTM)
-3.6
Beta
-1.68
Day Range
16.10p - 18.00p
52 Week Range
11.00p16.10p32.00p
16.10p
Upcoming Events
Q4 2025
Completion of toxicology studies for SDC-1801
SAR
NEUTRALSareum Appoints Oberon Capital as Sole Broker
The biotechnology company has appointed Oberon Capital as its new sole broker, effective immediately.
SAR
NEUTRALSareum Initiates Toxicology Studies for Lead TYK2/JAK1 Inhibitor
The biotechnology company has initiated a programme of toxicology studies for its lead autoimmune disease candidate, SDC-1801, as it prepares to advance the drug into Phase 2 clinical trials.
SAR
NEUTRALSareum Provides Update on TYK2/JAK1 and SRA737 Programmes
The biotechnology company reports progress on its TYK2/JAK1 inhibitor compounds and the SRA737 Checkpoint kinase 1 inhibitor programme.
SAR
NEUTRALSareum Raises £115,530 Through Warrant Exercise
The biotechnology company has raised £115,530 through the exercise of warrants, issuing new shares at a 21.875% discount to the previous closing price.
SAR
NEUTRALSareum Director Increases Stake
The executive chairman of this biotechnology company has purchased additional shares in the company.
SAR
NEUTRALSareum Holdings Provides Notice of Half-Year Results
The biotechnology company has announced it will release its half-year results on March 25th and hold an investor presentation on the same day.
SAR
BADSareum Raises £1.07M in Discounted Equity Fundraise
The biotechnology company has raised £1.07 million through a discounted equity fundraise, suggesting low investor confidence in the firm's prospects.
SAR
GOODSareum Acquires Licence for SRA737
The biotechnology company has acquired the licence for a clinical-stage cancer drug, SRA737, on improved economic terms, while also advancing its lead autoimmune disease candidate.